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The Prostacyclin Analog Beraprost Sodium Ameliorates
Characteristics of Metabolic Syndrome in Obese Zucker
(Fatty) Rats
Nahoko Sato, Masayuki Kaneko, Mitsutaka Tamura, and Hajimu Kurumatani
OBJECTIVE—The prostacyclin analog, beraprost sodium (BPS),
was examined for its potential to improve the symptoms of obesity-
type diabetes (i.e., hyperglycemia, hyperinsulinemia, dyslipidemia,
histopathologic changes, and diabetic complications).
RESEARCH DESIGN AND METHODS—Obese Zucker rats,
an experimental model of genetic obesity-induced type 2 diabe-
tes, were repeatedly administered BPS at oral doses of 0.2 or 0.6
mg  kg
1  day
1 b.i.d. for 12 weeks, and serum chemistry,
urinalysis, and histopathologic examination were performed.
RESULTS—BPS dose-dependently suppressed serum glucose,
insulin, triglyceride, and cholesterol levels in obese animals. In
oral glucose tolerance test, BPS suppressed the post–glucose-
loading elevation of serum glucose in a dose-dependent manner.
Urinary N-acetyl--D-glucosaminidase was signiﬁcantly lower in
BPS-treated obese animals compared with control animals, al-
though no signiﬁcant differences were observed in urinary pro-
tein levels between the BPS-treated groups and the control
group. In addition, histopathologic examination revealed signiﬁ-
cant protective effects of BPS against renal disorder in obese
animals. Histopathologically, BPS also inhibited the progression
of hepatic steatosis, hypertrophy of adipose tissue, and pancre-
atic ﬁbrosis. Furthermore, thermographic analysis of the hind
limb sole skin surface indicated a signiﬁcant increase in temper-
ature in BPS-treated animals, compared with control animals,
which was likely due to improved blood circulation by adminis-
tration of BPS.
CONCLUSIONS—BPS suppressed the pathogenesis and devel-
opment of diabetes and its complication, nephropathy, which
was presumably accompanied by improving glucose intolerance
and insulin resistance in obese Zucker rats. Diabetes 59:
1092–1100, 2010
D
iabetes has become a major health concern
worldwide. In fact, the number of patients with
diabetes is still increasing and currently ac-
counts for at least 5% of the adults in the world.
Among them, 30% of diabetic patients develop nephrop-
athy. The mechanisms underlying the pathogenesis of
diabetes and subsequent nephropathy are extremely com-
plex and have not yet been fully elucidated. Glucose
intolerance and insulin resistance, however, commonly
occur and are often accompanied by hyperglycemia and
hyperinsulinemia in diabetic patients, especially in those
with obesity-induced type 2 diabetes. These abnormalities
are also regarded as risk factors leading to macrovascular
and microvascular complications, such as myocardial in-
farction, nephropathy, retinopathy, and neuropathy (1).
Skeletal muscle, liver, and adipose tissues are insulin-
responsive organs that are considered to be closely asso-
ciated with glucose intolerance and insulin resistance.
Among them, skeletal muscle glucose disposal is a primary
defect that leads to the development of glucose intoler-
ance and type 2 diabetes (2,3). In addition, glucose imbal-
ance in diabetic patients is presumed to be closely
associated with poor secretion of the endogenous vasodi-
lator, NO, from endothelial cells and the resultant reduc-
tion of blood ﬂow (4). This reduction in blood ﬂow
presumably triggers further resistance of the skeletal
muscle to glucose disposal. It is well known that variety of
activity and distribution were observed in NO synthase
(NOS) according to its subtypes (5–8). Because there were
contradictory reports for involvement of subtypes such as
inducible NOS to diabetic condition in obese Zucker rats
(9,10), the role of NOS subtypes was still unclear. How-
ever, in the case of endothelial NOS (eNOS), decrease in
its activity would be closely related to the exacerbation of
diabetic conditions (6).
Beraprost sodium (BPS), the stable prostacyclin analog,
has potent vasodilating activity and activation effect of
eNOS expression in the endothelium (11,12). Based on the
vasodilating activity together with protection of the endo-
thelium, anti-inﬂammatory antiplatelet activities, and in-
creasing of eNOS production, BPS improves regional
blood ﬂow (13,14). Accordingly, BPS is expected to im-
prove insulin resistance, at least in part, by improving
blood ﬂow in muscle and consequently to ameliorate other
pathogenesis seen in type 2 diabetes. However, the poten-
tial of BPS against these pathologic conditions remains to
be elucidated.
Obese Zucker rats are widely used as a useful exper-
imental model for genetic obesity-induced type 2 diabe-
tes because development of the disease shares many
features with that in humans. Namely, these rats are
obese and develop progressive insulin resistance, glu-
cose intolerance, hyperinsulinemia, and hyperlipidemia
(15–17). Therefore, to verify the hypothesis that BPS
can improve insulin resistance and ameliorate the symp-
toms and complications of type 2 diabetes, we have
used Zucker rats as an animal model.
The present report describes the changes in some serum
chemistry parameters related to glucose and lipid metab-
olism and some urinary biomarkers, indicative of renal
function, in male obese Zucker rats treated with re-
peated oral BPS. Histopathologic examination, focusing
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kidney, and blood pressure and thermographic analyses
of changes in blood ﬂow are also described.
RESEARCH DESIGN AND METHODS
Animals. Male obese and lean Zucker rats (ZUC-Leprfa/Leprfa rats) were
purchased from Charles River Japan (Tokyo, Japan). Animals were housed in
an animal room where the light cycle and temperature were maintained from
0700 to 1900, and 23  2°C, respectively. Animals were allowed free access to
drinking water and standard rat chow (MF; Oriental Yeast, Tokyo, Japan). All
experiments were performed in compliance with the ethics standards for
animal studies in Toray Industries.
Drug treatment. BPS was administrated orally to obese Zucker rats at 0.2 or
0.6 mg  kg
1  day
1 b.i.d. from 7 to 19 weeks of age. Animals in the control
group were administered distilled water as a vehicle control, in place of BPS.
For each animal, body weight was measured at the beginning of each week
throughout the administration period. The body weight data were recorded as
a parameter for monitoring the general condition of the animal and were used
to determine the dosing volume administered to the animal each week.
Food consumption. Food consumption was measured at the time of urinalysis.
Blood. Blood was collected from animals once a week during the adminis-
tration period via the tail artery under ether anesthesia. Serum fractions were
obtained by centrifugation and used for the analysis of the following param-
eters with the respective enzyme assay kits: glucose (N-assay GLU-UL
Nittobo), triglyceride (TG) (N-assay L TG-H Nittobo), and total cholesterol
(Tcho) (N-assay L T-CHO-H Nittobo; all from Nittobo Medical, Tokyo, Japan).
Insulin was analyzed using a commercially available ELISA kit (Rat Insulin
ELISA; Mercodia, Uppsala, Sweden).
A1C was analyzed at 19 weeks of age using a commercially available kit
(NycoCard HbA1c; AXIS-SHIELD PoC AS, Kimbolton, U.K.). The value below
the lower limit of quantiﬁcation (3.0%) was treated as zero.
Urine. At 7, 13, and 17 weeks of age, animals were housed individually in
metabolic cages, and urine was collected in metabolic sampling bottles for
24 h. Urine was analyzed for the following parameters using commercially
available enzyme assay kits: total protein (Micro TP Test Kit; Wako, Osaka,
Japan) and N-acetyl--D-glucosaminidase (NAG) (NAG; N-assay L NAG Nit-
tobo; Nittobo Medical).
OGTT. At 18 weeks of age, after receiving the twice-daily administration of
BPS for 11 weeks, animals were subjected to an oral glucose tolerance test
(OGTT). Animals were administered the second daily dose and then fasted
overnight (16 h). Animals were administered 2 g/kg of glucose, and blood
samples were collected via the tail vein at 0, 0.5, 1, 2, and 4 h after the oral
glucose load. The blood samples were analyzed for serum glucose and insulin,
as described above.
Blood pressure. Systolic blood pressure and heart rate were measured in
conscious rats at 12 weeks of age using an automated noninvasive sphygmo-
manometer (BP-98A; Softron, Tokyo, Japan) equipped with a tail-cuff sensor.
Skin temperature. At 19 weeks of age, after receiving the twice-a-day
administration of BPS for 12 weeks, the skin temperature of the animals was
assessed using a thermograph (Neo Thermo TVS-700; NIPPON AVIONICS,
Tokyo, Japan). For each animal, the thermal image of the left hind leg was
recorded at 0 and 2 h after the ﬁrst administration of the day. The image was
analyzed for temperature at about 4,000 points in the area corresponding to
each hind leg, and the mean temperature was calculated using the software PE
professional (NIPPON AVIONICS).
Processing tissues for histopathologic evaluation. At the end of the
administration period, animals were exsanguinated via the abdominal aorta
under ether anesthesia. The kidney, pancreas, liver, and adipose tissue were
removed from each animal, ﬁxed in 10% neutral buffered formalin, and
embedded in parafﬁn. Thin sections were prepared from the parafﬁn blocks
and stained with hematoxylin-eosin (H-E) and periodic acid Schiff.
For the quantiﬁcation of areas of lipid accumulation in the liver, H-E–
stained images of the lean, control, and BPS groups were imported into a
computer for analysis. In each liver, ﬁve high-power ﬁelds were randomly
selected to extract porosity areas and the rate of lipid accumulation area was
calculated in each section by an image analysis system (MacSCOPE; Mitani,
Tokyo, Japan).
Glomerular lesions and tubulointerstitial ﬁbrosis were evaluated semiquan-
titatively. In brief, glomerular lesions were graded according to the severity of
lesions for each glomerulus, from 0 to 4 as follows; 0: no lesion, 1:
expansion of the mesangial area was observed, but there was no glomerulo-
sclerosis, 2: sclerosis of less than 50%, 3: 50–75% sclerosis, 4: more than
75% of glomerular tuft. Tubulointerstitial ﬁbrosis was graded according to the
area of injury in 20 randomly selected high-power ﬁelds (40) and were
graded according to the area of alteration from 0 to 5 as follows: 0: no lesion,
1: 10%, 2: 10–25%, 3: 25–50%, 4: 50–75%, 5: 75% in each left
kidney.
Statistical analysis. Body weight, food consumption, serum and urine
chemistry, blood pressure, heart rate, skin temperature, and histopathologic
data were expressed as the mean  SE. Statistical signiﬁcance between
BPS-treated group and control group was assessed using a two-way ANOVA,
followed by parametric Williams test (body weight, food consumption,
systolic blood pressure, heart rate, skin temperature, and hepatic steatosis)
and nonparametric Williams test (serum and urinary parameter, and renal
injury); and lean group and control obese group, by t test (body weight, food
consumption, systolic blood pressure, heart rate, sole temperature, and
hepatic steatosis) and Welch test (serum and urinary parameter, and renal
injury). The probability value of P  0.05 was considered statistically
signiﬁcant.
RESULTS
Body weight and food consumption. The body weight
was signiﬁcantly greater in obese Zucker rats in the
control group than in that for lean rats throughout the
administration period. In comparison, among the groups
of obese rats, the body weight was signiﬁcantly greater in
the 0.6-mg/kg BPS group than in the control group from 14
weeks of age to the end of the administration period (Fig.
1A). In the 0.2-mg/kg BPS group, the body weight was only
higher than the control group from 16 to 17 weeks of age.
Food consumption was signiﬁcantly high in obese Zucker
rats in the control group than in that for lean rats, but there
was no difference between control rats and BPS-treated
rats (Fig. 1B).
Hematologic examination. Serum glucose was signiﬁ-
cantly higher in obese Zucker rats than in lean rats from 11
weeks of age until the end of the administration period.
During this period, obese Zucker rats treated with 0.6
mg/kg BPS exhibited signiﬁcantly lower serum glucose
levels than the control Zucker rats (Fig. 1C). Serum insulin
was markedly elevated in control untreated obese Zucker
rats from 8 weeks of age, compared with lean rats. No
such elevation was observed in obese Zucker rats in the
0.6-mg/kg BPS group throughout the administration pe-
riod. Indeed, insulin levels were signiﬁcantly lower in the
0.6-mg/kg BPS group compared with the control group
(Fig. 1D). A1C tended to be dose dependently lowered by
BPS treatment (Fig. 1E).
Regarding the parameters related to lipid metabolism,
serum TGs were signiﬁcantly higher in control untreated
obese Zucker rats compared with lean animals throughout
the administration period. Serum TG levels, however,
were signiﬁcantly lower in the 0.6-mg/kg BPS group com-
pared with the control group (Fig. 1F). Similarly, serum
Tcho was signiﬁcantly higher in control Zucker rats than
in lean animals throughout the administration period.
Signiﬁcantly lower Tcho levels were observed in the
0.6-mg/kg BPS group, compared with those in the con-
trol group, from 10 to 15 weeks of age, but not for other
ages (Fig. 1G).
OGTT. After the glucose loading, control untreated obese
Zucker rats showed rapid and remarkable elevation of
serum glucose, whereas serum glucose elevation was
relatively slow and brief in lean rats (Fig. 2A). After
reaching a plateau 0.5–1 h after loading, serum glucose
was maintained at an essentially constant level in either
control untreated obese or lean animals until 4 h after
loading. Accordingly, serum glucose levels were signiﬁ-
cantly higher in control untreated obese animals than in
lean rats. The 0.6-mg/kg BPS group, however, showed a
less rapid and less remarkable serum glucose elevation,
compared with the control group.
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treated obese rats than in lean rats, even at the baseline,
and throughout the 4-h postloading observation period
(Fig. 2B). Compared with the control group, the 0.6-mg/kg
BPS group showed signiﬁcantly lower insulin levels at 0,
0.5, and 4 h after loading.
Urinalysis. As for urinary protein, a remarkable elevation
was observed in control untreated obese Zucker rats,
whereas lean animals exhibited only a slight elevation
(Fig. 3A). Thus, urinary protein was signiﬁcantly higher
than in lean rats from 7 weeks of age until the end of the
administration period. BPS apparently suppressed the
elevation of urinary protein level observed in obese Zucker
rats during the administration period, although these val-
ues were not signiﬁcantly different from the control group.
As for urinary NAG, gradual elevations were observed in
control untreated obese Zucker rats as well as in lean rats,
although the levels were signiﬁcantly higher in the former
than in the latter group (Fig. 3B). BPS suppressed the
elevation observed in obese Zucker rats, and a signiﬁcant
difference from the control group was detected in the
0.6-mg/kg BPS group at 17 weeks of age.
Serum creatinine level was not elevated in obese Zucker
rats and there were no differences between each group
(data not shown).
Blood pressure. The systolic blood pressure of obese
Zucker rats was higher than that of lean rats (P 	 0.054) at
12 weeks of age. Although BPS inhibited the elevation of
blood pressure (Fig. 3C), the heart rate was not different in
each group (Fig. 3D).
Skin temperature. Immediately before the daily admin-
istration, thermographic image analysis revealed that
there was no apparent change in the temperature in the
area corresponding to the left hind leg among BPS-treated
obese Zucker rats, control untreated obese Zucker rats,
and lean rats (data not shown). At 2 h after administration,
the skin temperature in the hind leg area was signiﬁcantly
higher in the 0.6-mg/kg BPS-treated group than in the
control group (Fig. 4A and B).
Morphology. Compared with the pancreatic islets in lean
animals, control untreated obese Zucker rats exhibited
obviously severe hypertrophic, lobed, and ﬁbrotic changes.
In obese rats treated repeatedly with BPS for 12 weeks, these
changes were less extensive (Fig. 5).
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FIG. 1. Body weight (BW) (A), food consumption (B), serum glucose (C), insulin (D), A1C
(E), TG (F), and total cholesterol (G) in control obese Zucker rats (F), obese Zucker rats
treated with BPS (‚, 0.2 mg  kg
1  day
1; Œ, 0.6), and Zucker lean rats (E) as line graph, and
control obese Zucker rats (), Zucker rats treated with BPS (o, 0.2 mg  kg
1  day
1; f, 0.6),
and Zucker lean rats (u) as bar graph. Data are mean  SE of 7–8 rats. *P < 0.05, **P < 0.01
versus control rats by parametric Williams test (body weight, food consumption) and
nonparametric Williams test (glucose, insulin, TG, and total cholesterol). #P < 0.05, ##P <
0.01 versus control by t test (body weight, food consumption) and Welch test (glucose,
insulin, TG, and total cholesterol).
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lation of higher levels of lipid in hepatic intracellular
vesicles and ballooning degeneration of hepatocytes, was
evident in obese Zucker rats (Fig. 6A). By contrast, BPS
treatment markedly reduced lipid accumulation and bal-
looning degeneration of hepatocytes (Fig. 6A and B).
Adipocytes were obviously larger in obese rats com-
pared with lean animals. Adipose tissues from BPS-treated
rats, however, exhibited greater populations of much
smaller adipocytes (Fig. 7).
Compared with kidney tissues from lean rats, control
untreated obese Zucker rats exhibited focal and segmental
glomerulosclerosis and expansion of glomerular matrix
(Fig. 8A, arrowhead). Furthermore, tubular damage such
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FIG. 3. Urinary protein (A), NAG (B), systolic blood pressure (SBP) (C), and heart rate (D) in control obese Zucker rats (F), obese Zucker rats
treated with BPS (‚, 0.2 mg  kg
1  day
1; Œ, 0.6), and Zucker lean rats (E) as line graph, and control obese Zucker rats (), Zucker rats treated
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1; f, 0.6), and Zucker lean rats (u) as bar graph. Data are mean  SE of 7–8 rats. *P < 0.05 versus control rats
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ﬁgure is available in the online issue.)
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FIG. 6. Photomicrographs of H-E staining of the liver in control obese
Zucker rats, obese Zucker rats treated with BPS, and Zucker lean rat
(A) and quantitative analysis of vesicles in control obese Zucker rats
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1  day
1;
f, 0.6) (B). Data are mean  SE of 7–8 rats. **P < 0.01 versus control
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FIG. 7. Photomicrographs of H-E staining of the adipose tissues in
control obese Zucker rats, obese Zucker rats treated with high-dose of
BPS, and Zucker lean rat. (A high-quality digital representation of this
ﬁgure is available in the online issue.)
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tubular basement membranes, and inﬁltration of inﬂam-
matory cells were also observed in obese Zucker rats (Fig.
8A, arrow). These changes were comparatively mild in
kidney tissues from obese Zucker rats treated repeatedly
with BPS. In fact, semiquantitative histopathologic analy-
sis indicated that both glomerular and tubular abnormality
scores were signiﬁcantly lower in obese Zucker rats
treated with BPS at either 0.2 or 0.6 mg/kg compared with
in control untreated obese rats (Fig. 8B).
DISCUSSION
In the present study, we examined the effects of the
prostacyclin analog BPS to improve various diabetic mark-
ers in obese Zucker rats; an animal model whose patho-
logic condition resembles that seen in human genetic
obesity-induced type 2 diabetes. Speciﬁcally, BPS inhib-
ited the increases in blood glucose, insulin, TG, total
cholesterol, and blood pressure, and ameliorated the de-
velopment of glucose intolerance and insulin resistance.
Histopathologically, BPS inhibited the progression of he-
patic steatosis, hypertrophy of the adipose cells, pancre-
atic ﬁbrosis, and renal damage. Thus, we revealed that
BPS suppressed the pathogenesis and development of
diabetes, which was presumably accompanied by improv-
ing glucose intolerance and insulin resistance.
Insulin resistance plays a central role in the develop-
ment of diabetes. The muscles, liver, and adipocytes are
deeply involved in the utilization of glucose as insulin-
responsive organs, and are, thus, closely related to insulin
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FIG. 8. Photomicrographs of periodic acid Schiff staining of the kidney in control obese Zucker rats, obese Zucker rats treated with BPS, and
Zucker lean rat (A) and semiquantitative analysis of glomerular (B, left) and tubular (B, right) injuries in control obese Zucker rats (), obese
Zucker rats treated with BPS (o, 0.2 mg  kg
1  day
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versus control by nonparametric Williams test. ##P < 0.01 versus control by Wilcoxon test. (A high-quality digital representation of this ﬁgure
is available in the online issue.)
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the liver is decreased with increasing levels of glucose
and lipids in blood (2,18–21). In adipocytes, the secretion
of cytokines, such as tumor necrosis factor-
 (TNF-
)
and monocyte chemoattractant protein 1 (MCP-1), is
increased, consistent with enlargement of adipocytes
caused by excessive accumulation of adipose and with
inﬁltration of inﬂammatory cells, such as macrophages.
It is known that these changes may decrease insulin
signaling (22,23).
When the action of insulin decreased through insulin
resistance, abnormal metabolism of glucose and lipid is
the result, furthering development of diabetes. Therefore,
it is especially important to improve insulin resistance to
prevent development of diabetes.
In this study, we demonstrated that BPS inhibited the
development of diabetes in obese Zucker rats, probably by
improving insulin resistance. Although the mechanisms
underlying the ﬁndings of this study remain uncertain, we
discussed the following hypothesis.
In patients with diabetes, the vasodilating response was
decreased by reduced production of NO from the endo-
thelium, and structural and functional disorder of capillary
blood vessels and decreasing muscle blood ﬂow was
caused (24,25). In Zucker rats, in addition to insulin
resistance, microvascular density, blood ﬂow, and re-
sponsiveness of insulin-stimulated glucose metabolism
in muscles (26,27), together with activity of prostacyclin
(PGI2) synthase and eNOS in blood vessels (5), were
decreased. In addition, endothelium-dependent relax-
ation was ameliorated together with enhanced eNOS
activity and reduced superoxide anion release in the
aorta of obese Zucker rats by polyphenol treatment (6).
Based on these observations, it was considered that
reduced production of NO by decreased eNOS activity
together with microvascular disturbances would be
closely related to exacerbated diabetic conditions, es-
pecially insulin resistance. Reduced PGI2 also might be
involved in induction of insulin resistance, either di-
rectly or through lowered NO production.
BPS, a PGI2 derivative, exhibits direct actions on
smooth muscle cells to elicit vasodilatation, and increase
NO production by facilitating expression of eNOS mRNA
in endothelial cells as well (11,12). It is also known that
BPS can protect the endothelium from high levels of
glucose and other cytotoxic agents (28). In addition, BPS
ameliorated the decrease in NO production in the endo-
thelial cells of streptozocin-induced diabetic model rats
(29). Therefore, BPS is supposed to improve insulin resis-
tance through its vasodilating activity, protective effects
on vascular endothelial cells, and the facilitation of NO
production, and, as a result, amelioration of blood ﬂow in
muscles. In this study, increased muscle blood ﬂow was
conﬁrmed, based on the data regarding skin temperature
obtained after BPS administration.
It is also known that diabetes may be improved by
increasing fatty acid oxidation and energy consumption in
muscles (30), and it was conﬁrmed that insulin resistance
was improved by increased thermogenesis and energy
consumption in Zucker rats (31). Therefore, it is sug-
gested that BPS improved insulin resistance by in-
creased thermogenesis and energy metabolism, as a
consequence of increasing blood ﬂow in muscles.
Adipocytes also play a central role in energy metabo-
lism, and can store energy, especially through the intake of
free fatty acids, in an insulin-dependent manner. When the
amount of accumulated fat is increased by hyperlipidemia,
enlarged adipocytes and inﬁltrating macrophages produce
cytokines, such as MCP-1 and TNF-
, which are consid-
ered to be closely related to the deterioration of insulin
resistance. In this study, it was clariﬁed that increases in
blood TGs and enlargement of adipocytes were inhibited
by BPS treatment. It was reported that serum levels of
TNF-
 and MCP-1 were increased in Zucker rats (32,33),
and BPS could exhibit an inhibitory action on the produc-
tion of MCP-1 and TNF-
 in another models (34,35).
Moreover, lipolytic activity was increased when produc-
tion of PGI2 was increased in adipose tissues (36). Based
on these facts, it was supposed that BPS improved insulin
resistance by reducing the enlargement of adipocytes and
production of developmental factors, such as MCP-1 and
TNF-
.
In recent years, it has also been reported that BPS can
enhance peroxisome proliferator–activated receptor-
(37). GW501516, peroxisome proliferator–activated recep-
tor- agonist, is considered to facilitate fatty acid oxida-
tion in muscles, and improve insulin resistance and
obesity (30). Thus, this action by BPS may be involved in
the improvement of insulin resistance in Zucker rats.
In histopathologic examination, we clariﬁed that BPS
would have effects, not only to improve the functional
disturbance of insulin resistance but also to improve tissue
disturbance in the pancreas, liver, and kidney, which are
characteristic of patients with diabetes. In this model,
ﬁbrosis, caused by deterioration of the pancreas when
insulin secretion associated with insulin resistance was
increased continuously, was improved by the administra-
tion of BPS. The possibility exists that both direct protec-
tive action of BPS on the pancreas, including the inhibition
of vascular endothelial disorders, and indirect inhibitory
action on increased insulin by improving insulin resistance
may be involved in the improvement of ﬁbrosis.
Regarding the liver, it is known that hepatic steatosis
often occurs in patients with obesity-induced type 2 dia-
betes, and as mentioned above, insulin resistance is deeply
involved. In this study, vacuoles, caused by the accumula-
tion of adipose in hepatic cells, were observed in Zucker
rats and were improved by BPS. Because BPS inhibits
increases of blood glucose and TGs, and improves insulin
resistance, these actions are considered to be comprehen-
sively involved in the inhibition of the development of
hepatic steatosis. In addition, the direct protective action
of BPS on hepatic cells (38) may contribute to improve-
ments in the hepatic steatosis.
Diabetic nephropathy is one of the major complications
among patients with diabetes. It is important to inhibit the
development of renal disorder for improving the prognosis
of diabetic patients. In this study, characteristic morpho-
logic changes such as segmental glomerulosclerosis, ex-
pansion of glomerular matrix, tubular damage such as
tubular atrophy, interstitial ﬁbrosis, thickening of the
tubular basement membranes, and inﬁltration of inﬂam-
matory cells, which were also seen in human diabetic
nephropathy, were observed, although nodular glomerulo-
sclerosis was not observed up to 19 weeks of age in this
study, and these changes were improved by the adminis-
tration of BPS. In Zucker rats, decreased NOS (eNOS)
expression in the kidney was observed concomitant with
renal injury (39), and renal damage was caused when NO
production was inhibited by administration of L-N
G-nitro-
L-arginine methyl ester (40). Thus, it was suggested that
decreased production of NO would be involved in the
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1098 DIABETES, VOL. 59, APRIL 2010 diabetes.diabetesjournals.orgdevelopment of renal disorder and there is the possibility
that increased NO production upon administration of BPS
may inhibit the development of nephropathy. In addition,
because it is known that insulin resistance is involved in
renal injury in this model (41), the improvement in insulin
resistance by BPS also may contribute to the improvement
of renal damage. In OLETF rats, another obesity-type
diabetes model, renal disorder was also inhibited by BPS.
By contrast, because blood glucose did not change prom-
inently at the stage of OLETF rats, effect of BPS against
blood glucose was unclear (42). Furthermore, it has been
reported that in the renal failure model with no evidence
of diabetes, BPS could inhibit the development of renal
disorder (35,43). Therefore, there is the another possibility
that in addition to the inhibitory effect on development
observed in improvement of diabetes, the direct inhibitory
action against renal disorder may be somehow involved in
the inhibition of renal damage by BPS observed in Zucker
rats. BPS maintained blood pressure over time in Zucker
rats to the same level as that in lean rats. Because
increased blood pressure and renal damage are observed
in patients with diabetes (44), and these are correlated
with each other (45,46), inhibition of blood pressure by
BPS may be related to inhibition of renal disorder
development.
Like other antidiabetic agents (47,48), diabetic condi-
tions such as hyperglycemia and hyperlipidemia were
ameliorated despite constant increasing of body weight by
BPS treatment. Because food consumption was not in-
creased and edema was not observed in BPS-treated rats,
we supposed that mild increase in body weight of BPS-
treated rats might be the ameliorating effect of glucose
utilization by BPS treatment.
As for the involvement of increased NO production and
eNOS activity for the beneﬁcial effect of BPS, further
investigation would be needed focusing on the local
expression of eNOS and other NOS subtypes in the artery,
kidney, and other related organs.
Taken together, using Zucker rats, an experimental
model of genetic obesity-induced type 2 diabetes, we
succeeded in revealing for the ﬁrst time that BPS, a
prostacyclin analog, would improve a variety of markers
of obesity-type diabetes and nephropathy, one of diabetic
complications, in addition to tissue disturbance in the
liver, adipocytes, and pancreas. And it is considered that
improvement of insulin resistance by BPS treatment may
contribute to ameliorating these pathologic conditions.
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